west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "YI Chenggang" 2 results
  • PROGRESS OF TISSUE ENGINEERING RESEARCH IN VASCULARIZED TISSUE ENGINEERING CHAMBER IN VIVO

    Objective To introduce a new method of tissue engineering research by transplanting vessels to tissue engineering chamber (vascularized tissue engineering chamber) in vivo, and to review the progress of research in vascularized tissue engineering chamber. Methods The l iterature concerning all kinds of tissue engineering research in chamber was reviewed, analysed, and summarized. Results The use of vascularized tissue engineering chamber allowed generation of vascularized adipose tissue, cardiac tissue, and so on. The most common tissue engineering chamber models were arterio-venous loop model and inferior epigastric artery model. Conclusion The method of tissue engineering research by using vascularized tissue engineering chamber has a potential cl inical value and provides a promising future.

    Release date:2016-08-31 05:42 Export PDF Favorites Scan
  • ADVANTAGES AND DISADVANTAGES OF COMPOSITE TISSUE ALLOTRANSPLANTATION

    Objective To review the research progress of composite tissue allotransplantation (CTA), analyzethe superiority and the inferiority, and inform the possible direction of further research. Methods Literature concerningCTA was reviewed and analyzed in terms of the l imits of conventional reparative and reconstructive surgery, the definitionof CTA, potential advantages, and treatment risks. Results The cl inical research of CTA both at home and abroad proved that the therapeutic effect of CTA was better than that of conventional reparative and reconstructive surgery. However, therisks resulting from immunosuppressive therapy were still the primary factors restraining the wide cl inical appl ication ofCTA. Conclusion The development of immunosuppressive therapy explores a great development potential for the CTA, and how to decrease the treatment risk of immunosuppressive therapy will be the main research direction in the field of CTA.

    Release date:2016-09-01 09:08 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content